About Us

Our Company

We are dedicated to the discovery and development of small molecule therapeutics targeting fundamental biological pathways of cancer. Our experienced team is comprised of industry leaders with proven track records in the discovery, clinical development, and commercialization of innovative cancer therapies. Leveraging our extensive industry experience and know-how, we developed our Integrated Discovery Engine—our working model for generating potentially differentiated product candidates. This approach has allowed us to advance a diverse pipeline in a capital efficient manner, clearing four INDs with the FDA in five years. We believe our deep pipeline of oncology therapeutics has the potential to significantly improve the lives of patients with various types of cancer.

We are advancing our lead candidate, ZN-c5, for the treatment of ER+/HER2- advanced or metastatic breast cancer. ZN-c5 is an oral selective estrogen receptor degrader (SERD) currently being evaluated in a Phase 1/2 study both as a monotherapy and in combination with palbociclib (marketed as Ibrance® by Pfizer) through a clinical research collaboration with Pfizer. We are also pursuing additional product candidates (WEE1 inhibitor, BCL-2 inhibitor, EGFR inhibitor) targeting distinct cancer pathways that address large patient populations.

Partners & Collaborations

Please contact us at bd@nullzentalis.com to discuss partnering and collaborations opportunities.